These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 1718212)

  • 1. In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes.
    Sawant-Mane S; Clark MB; Koski CL
    Ann Neurol; 1991 Apr; 29(4):397-404. PubMed ID: 1718212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral mechanisms in immune neuropathies.
    Koski CL
    Neurol Clin; 1992 Aug; 10(3):629-49. PubMed ID: 1501599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demyelination in vivo by Guillain-Barré syndrome and other human serum.
    Brown MJ; Rosen JL; Lisak RP
    Muscle Nerve; 1987; 10(3):263-71. PubMed ID: 3561445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome.
    Saida T; Saida K; Lisak RP; Brown MJ; Silberberg DH; Asbury AK
    Ann Neurol; 1982 Jan; 11(1):69-75. PubMed ID: 7059130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demyelination induced by serum from patients with Guillain-Barré syndrome.
    Harrison BM; Hansen LA; Pollard JD; McLeod JG
    Ann Neurol; 1984 Feb; 15(2):163-70. PubMed ID: 6703656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effector mechanisms of PNS demyelination in Gal-C induced-EAN].
    Saida K
    Rinsho Shinkeigaku; 1990 Dec; 30(12):1361-3. PubMed ID: 2129197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of terminal components of complement in patients with Guillain-Barré syndrome and other demyelinating neuropathies.
    Koski CL; Sanders ME; Swoveland PT; Lawley TJ; Shin ML; Frank MM; Joiner KA
    J Clin Invest; 1987 Nov; 80(5):1492-7. PubMed ID: 3680509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on demyelination in vitro: the requirement of membrane attack components of the complement system.
    Liu WT; Vanguri P; Shin ML
    J Immunol; 1983 Aug; 131(2):778-82. PubMed ID: 6863930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of complement-fixing antibodies to peripheral nerve myelin in Guillain-Barré syndrome.
    Koski CL
    Ann Neurol; 1990; 27 Suppl():S44-7. PubMed ID: 2194426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical correlation with anti-peripheral-nerve myelin antibodies in Guillain-Barré syndrome.
    Koski CL; Gratz E; Sutherland J; Mayer RF
    Ann Neurol; 1986 Jun; 19(6):573-7. PubMed ID: 3729311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome.
    Wanschitz J; Maier H; Lassmann H; Budka H; Berger T
    Brain; 2003 Sep; 126(Pt 9):2034-42. PubMed ID: 12847075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies.
    Willison HJ; Trapp BD; Bacher JD; Dalakas MC; Griffin JW; Quarles RH
    Muscle Nerve; 1988 Nov; 11(11):1169-76. PubMed ID: 2465494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Guillain-Barré syndrome].
    Piradov MA; Lozhnikova SM; Sakharova AV; Liudkovskaia IG; Nikitin SS
    Arkh Patol; 1994; 56(5):73-9. PubMed ID: 7535047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis.
    Hartung HP; Reiners K; Schmidt B; Stoll G; Toyka KV
    Ann Neurol; 1991 Jul; 30(1):48-53. PubMed ID: 1929228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of neuropathies associated with elevated IgM serum levels.
    Goldfarb AR; Sander HW; Brannagan TH; Magda P; Latov N
    J Neurol Sci; 2005 Feb; 228(2):155-60. PubMed ID: 15694197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology of the motor-sensory axonal Guillain-Barré syndrome.
    Griffin JW; Li CY; Ho TW; Tian M; Gao CY; Xue P; Mishu B; Cornblath DR; Macko C; McKhann GM; Asbury AK
    Ann Neurol; 1996 Jan; 39(1):17-28. PubMed ID: 8572662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy.
    Hafer-Macko CE; Sheikh KA; Li CY; Ho TW; Cornblath DR; McKhann GM; Asbury AK; Griffin JW
    Ann Neurol; 1996 May; 39(5):625-35. PubMed ID: 8619548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum antibodies to gangliosides in Guillain-Barré syndrome.
    Ilyas AA; Willison HJ; Quarles RH; Jungalwala FB; Cornblath DR; Trapp BD; Griffin DE; Griffin JW; McKhann GM
    Ann Neurol; 1988 May; 23(5):440-7. PubMed ID: 3133978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
    Rus H; Cudrici C; Niculescu F; Shin ML
    J Neuroimmunol; 2006 Nov; 180(1-2):9-16. PubMed ID: 16905199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome.
    Sharief MK; McLean B; Thompson EJ
    Ann Neurol; 1993 Jun; 33(6):591-6. PubMed ID: 8498839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.